Everence Capital Management Inc. lifted its position in Johnson & Johnson (NYSE:JNJ – Free Report) by 3.6% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 73,341 shares of the company’s stock after acquiring an additional 2,560 shares during the period. Johnson & Johnson accounts for 0.7% of Everence Capital Management Inc.’s holdings, making the stock its 21st largest position. Everence Capital Management Inc.’s holdings in Johnson & Johnson were worth $11,886,000 at the end of the most recent quarter.
A number of other institutional investors have also recently made changes to their positions in the company. Innealta Capital LLC acquired a new position in Johnson & Johnson during the second quarter worth $27,000. MFA Wealth Advisors LLC acquired a new position in Johnson & Johnson during the second quarter worth $43,000. Fairfield Financial Advisors LTD acquired a new position in Johnson & Johnson during the second quarter worth $46,000. Fairway Wealth LLC boosted its stake in Johnson & Johnson by 217.1% during the second quarter. Fairway Wealth LLC now owns 333 shares of the company’s stock worth $49,000 after buying an additional 228 shares during the last quarter. Finally, Quarry LP acquired a new position in Johnson & Johnson during the second quarter worth $49,000. 69.55% of the stock is owned by institutional investors and hedge funds.
Insiders Place Their Bets
In other news, VP Robert J. Decker sold 5,635 shares of the stock in a transaction dated Friday, August 30th. The stock was sold at an average price of $165.06, for a total value of $930,113.10. Following the transaction, the vice president now owns 18,973 shares in the company, valued at approximately $3,131,683.38. This represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. 0.16% of the stock is owned by company insiders.
Analyst Upgrades and Downgrades
View Our Latest Analysis on Johnson & Johnson
Johnson & Johnson Price Performance
Shares of NYSE JNJ opened at $162.85 on Tuesday. The stock’s 50-day moving average is $163.04 and its two-hundred day moving average is $154.77. The company has a debt-to-equity ratio of 0.44, a current ratio of 1.07 and a quick ratio of 0.85. Johnson & Johnson has a 1-year low of $143.13 and a 1-year high of $168.85. The company has a market cap of $391.92 billion, a price-to-earnings ratio of 10.15, a price-to-earnings-growth ratio of 2.65 and a beta of 0.52.
Johnson & Johnson (NYSE:JNJ – Get Free Report) last issued its quarterly earnings results on Tuesday, October 15th. The company reported $2.42 earnings per share for the quarter, topping the consensus estimate of $2.21 by $0.21. Johnson & Johnson had a return on equity of 36.60% and a net margin of 46.34%. The company had revenue of $22.47 billion for the quarter, compared to the consensus estimate of $22.17 billion. During the same quarter in the prior year, the business earned $2.66 EPS. Johnson & Johnson’s revenue was up 5.2% on a year-over-year basis. Analysts forecast that Johnson & Johnson will post 10 EPS for the current fiscal year.
Johnson & Johnson Announces Dividend
The business also recently declared a quarterly dividend, which will be paid on Tuesday, December 10th. Shareholders of record on Tuesday, November 26th will be issued a dividend of $1.24 per share. The ex-dividend date of this dividend is Tuesday, November 26th. This represents a $4.96 annualized dividend and a yield of 3.05%. Johnson & Johnson’s dividend payout ratio (DPR) is 30.92%.
Johnson & Johnson Company Profile
Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.
Featured Articles
- Five stocks we like better than Johnson & Johnson
- 3 Stocks to Protect Your Portfolio from the Coronavirus Contagion
- Analysts Predict New Highs for Cybersecurity Stock by Christmas
- REIT Stocks – Best REIT Stocks to Add to Your Portfolio Today
- Nuclear Power Reaches Critical Mass: Top Stocks to Watch Now
- Energy and Oil Stocks Explained
- 2 Energy Stocks Surging on Billion-Dollar DOE Loan Commitments
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ – Free Report).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.